Septal reduction therapies for obstructive hypertrophic cardiomyopathy: Current strategies and evolving innovations

In symptomatic patients with obstructive hypertrophic cardiomyopathy, the management of left ventricular outflow tract obstruction remains the central therapeutic challenge. Despite recent advances in pharmacologic therapy, septal reduction therapy continues to represent the gold standard for relieving obstruction. Among available techniques, transaortic septal myectomy and percutaneous alcohol septal ablation are the most widely practiced and well-established procedures. In recent years, novel techniques employing alternative approaches or energy sources have emerged, including transapical beating-heart septal myectomy, transcatheter septal myotomy, percutaneous intramyocardial septal radiofrequency ablation, transcatheter endocardial septal radiofrequency ablation, and stereotactic septal radio ablation. These procedures share a common mechanistic principle-thinning the hypertrophied basal interventricular septum to mitigate systolic anterior motion of the mitral valve and thereby reduce obstruction. Preliminary studies have demonstrated promising efficacy and procedural safety, suggesting that some of these new modalities may be valuable adjuncts or potential alternatives to conventional therapies. Nonetheless, long-term, multicenter, and prospective data are necessary to establish their durability, safety, and clinical outcomes before broad clinical implementation.